All News
Filter News
Found 1,464 articles
-
Ventus Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
9/6/2023
Ventus Therapeutics announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 8:50 AM ET.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 05, 2023
9/5/2023
Blueprint Medicines Corporation, announced that, effective September 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 8,446 shares of its common stock and an aggregate of 4,221 restricted stock units to six new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program
8/31/2023
Alkermes plc announced the recipients of the 2023 Alkermes Inspiration Grants® program.
-
Recludix Pharma to Participate in Multiple Investor Conferences in September 2023
8/30/2023
Recludix Pharma announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present at multiple investor conferences in September.
-
Metrodora Institute Announces Healthcare and Biotech Leader, John B. Wirthlin, as CEO
8/30/2023
Metrodora Institute, an innovative medical and research center dedicated to advancing care, treatments, and cures for people living with complex, chronic diseases, announced that it has appointed John B. Wirthlin as Chief Executive Officer.
-
Ventus Therapeutics Named a “Fierce 15” Biotech Company of 2023
8/28/2023
Ventus Therapeutics announced that it has been named a “Fierce 15” company in Fierce Biotech’s 2023 annual report featuring the most innovative and promising biotechnology companies in the industry.
-
3rd ICPO Forum for Theranostics in Precision Oncology to be held at Garching, Munich on October 12th and 13th, 2023
8/23/2023
Since 2019 the International Centers for Precision Oncology is a German foundation working to enable growing numbers of Cancer Patients worldwide to get access to highly effective diagnostics and treatments in Radiomolecular Precision Oncology.
-
The RET kinase inhibitor showed “statistically significant and clinically meaningful improvements” in progression-free survival compared to Exelixis’ Cabometyx and Sanofi’s Caprelsa.
-
Ventus Therapeutics Initiates Dosing in a Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
8/22/2023
Ventus Therapeutics announced today that the first participant has been dosed in a Phase 1 clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor.
-
Champions Oncology Announces Remarkable Lineup of Speakers at Its Translational Oncology Symposium in Boston in September 2023
8/22/2023
Champions Oncology, Inc. kicks-off its annual series of events by hosting a scientific symposium at the Museum of Science, in Boston, Massachusetts on September 26th.
-
QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT® (avapritinib) in gastrointestinal stromal tumors
8/7/2023
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. Food and Drug Administration (FDA) approval of its therascreen PDGFRA RGQ PCR kit (therascreen PDGFRA kit).
-
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
8/3/2023
Xilio Therapeutics, Inc., a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, announced the promotion of Chris Frankenfield to chief operating officer of Xilio.
-
Blueprint Medicines Reports Second Quarter 2023 Results
8/2/2023
Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2023.
-
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
7/20/2023
Recludix Pharma today announced that the company has entered into a strategic collaboration with Sanofi (NASDAQ: SNY) to develop and commercialize first-in-class oral small molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory (I&I) diseases.
-
The Caris Precision Oncology Alliance Welcomes University Hospitals Seidman Cancer Center
7/19/2023
Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that University Hospitals Seidman Cancer Center has joined the Caris Precision Oncology Alliance™.
-
Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023
7/19/2023
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, August 2, 2023 , to report its second quarter financial results and provide a corporate update.
-
The Caris Precision Oncology Alliance Welcomes The Broad Institute of MIT and Harvard
7/13/2023
Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that the Broad Institute of MIT and Harvard has joined the Caris Precision Oncology Alliance™.
-
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
7/11/2023
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, announced the appointment of Habib Dable as a member of Aerovate’s Board of Directors.
-
Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
7/10/2023
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced the resignation of Dr. Joel Naor, Chief Medical Officer, effective July 15th, 2023.
-
The Caris Precision Oncology Alliance Welcomes the Icahn School of Medicine at Mount Sinai
7/6/2023
Caris Life Sciences® announced that the Icahn School of Medicine at Mount Sinai, in New York, NY, has joined the Caris Precision Oncology Alliance™ and will collaborate with Caris on various research projects.